Amicus Therapeutics
$10.069876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$10.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.31 (-2.91%) Today
-$0.29 (-2.80%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell FOLD and other stocks, options, and ETFs commission-free!
About FOLD
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with rare metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Cranbury, NJ. The listed name for FOLD is Amicus Therapeutics, Inc. Common Stock.
CEO
John Francis Crowley
Employees
584
Headquarters
Philadelphia, Pennsylvania
Founded
2002
Market Cap
2.97B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
5.96M
High Today
$10.90
Low Today
$10.05
Open Price
$10.60
Volume
4.90M
52 Week High
$25.39
52 Week Low
$6.25
FOLD News
Analyst Ratings
27%
of 11 ratings
Buy
27%
Hold
73%
Sell
0%
FOLD Earnings
-$0.36
-$0.31
-$0.25
-$0.20
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.23 per share
Actual
-$0.27 per share